A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis

A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis

Abstract Background Drug-drug interaction management is complex. Nirmatrelvir/ritonavir is a potent cytochrome P450 (CYP) 3A inhibitor and influences pharmacokinetics of co-administered drugs. Although there are several reports about drug-drug interactions of nirmatrelvir/ritonavir, an influence of...

Full description

Bibliographic Details
Main Authors: Ayumi Tsuzawa, Yoshiki Katada, Keisuke Umemura, Mitsuhiro Sugimoto, Asami Nishikawa, Yu-ki Sato, Yuko Yoshida, Noriaki Kitada, Atsushi Yonezawa, Daisuke Nakajima, Hiroshi Date, Tomohiro Terada
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Tacrolimus
Nirmatrelvir/ritonavir
Itraconazole
Novel coronavirus disease 2019
Drug-drug interaction
Lung transplantation
Online Access:https://doi.org/10.1186/s40780-023-00280-3

Internet

https://doi.org/10.1186/s40780-023-00280-3

Similar Items